Phase2/Proof of concept,Ponezumab treatment in participants with CAA

• Research type

  Research Study

• Full title

  A PHASE 2, RANDOMISED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF PF-04360365 (PONEZUMAB) IN ADULT SUBJECTS WITH PROBABLE CEREBRAL AMYLOID ANGIOPATHY

• IRAS ID

  129829

• Contact name

  David Werring

• Contact email

  david.werring@uclh.nhs.uk

• Sponsor organisation

  PFIZER INC

• Eudract number

  2013-001557-27

• Clinicaltrials.gov Identifier

  NCT01821118

• REC name

  London - South East Research Ethics Committee

• REC reference

  13/LO/1485

• Date of REC Opinion

  13 Jan 2014

• REC opinion

  Further Information Favourable Opinion